Abstract CV Therapeutics, under license from Roche (formerly Syntex), is developing ranolazine (Ranexa), a metabolic modulator and a partial fatty acid oxidation inhibitor, for the potential treatment of angina and acute coronary syndromes. By October 2004, enrollment in the phase III MERLIN TIMI-36 study was ongoing and the company anticipated completion by the end of the first quarter of 2005.
Ranolazine CV Therapeutics
MARZILLI, MARIO
2005-01-01
Abstract
Abstract CV Therapeutics, under license from Roche (formerly Syntex), is developing ranolazine (Ranexa), a metabolic modulator and a partial fatty acid oxidation inhibitor, for the potential treatment of angina and acute coronary syndromes. By October 2004, enrollment in the phase III MERLIN TIMI-36 study was ongoing and the company anticipated completion by the end of the first quarter of 2005.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
